NCT06900075View on ClinicalTrials.gov

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

March 31, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

Efsubaglutide Alfa 3mg Q2W and 1mg QW

Efsubaglutide Alfa 3 mg administered once every two weeks for 8 weeks, followed by a switch to Efsubaglutide Alfa 1 mg administered once weekly for an additional 8 weeks of treatment.

DRUG

Efsubaglutide Alfa 1mg QW and 3mg Q2W

Efsubaglutide Alfa 1 mg administered once weekly for 8 weeks, followed by a switch to Efsubaglutide Alfa 3 mg administered once every two weeks for an additional 8 weeks of treatment.

All Listed Sponsors
lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER